This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Hepatitis
  • /
  • Occurrence of hepatocellular carcinoma after direc...
Journal

Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.

Read time: 1 mins
Published:30th Jun 2019
Author: Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C et al.
Availability: Pay for access, or by subscription
Ref.:Expert Opin Drug Saf. 2019;18(7):603-610.
DOI:10.1080/14740338.2019.1617272
Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis


Introduction:
Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs).

Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC.

Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.

 

Read abstract on library site

Access full article